114 related articles for article (PubMed ID: 38742901)
1. Optimization of quenched fluorescent peptide substrates of SARS-CoV-2 3CL
Cesar Ramos de Jesus H; Solis N; Machado Y; Pablos I; Bell PA; Kappelhoff R; Grin PM; Sorgi CA; Butler GS; Overall CM
J Virol; 2024 Jun; 98(6):e0004924. PubMed ID: 38742901
[TBL] [Abstract][Full Text] [Related]
2. Active site specificity profiling of the matrix metalloproteinase family: Proteomic identification of 4300 cleavage sites by nine MMPs explored with structural and synthetic peptide cleavage analyses.
Eckhard U; Huesgen PF; Schilling O; Bellac CL; Butler GS; Cox JH; Dufour A; Goebeler V; Kappelhoff R; Keller UAD; Klein T; Lange PF; Marino G; Morrison CJ; Prudova A; Rodriguez D; Starr AE; Wang Y; Overall CM
Matrix Biol; 2016 Jan; 49():37-60. PubMed ID: 26407638
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV 3CL protease cleaves its C-terminal autoprocessing site by novel subsite cooperativity.
Muramatsu T; Takemoto C; Kim YT; Wang H; Nishii W; Terada T; Shirouzu M; Yokoyama S
Proc Natl Acad Sci U S A; 2016 Nov; 113(46):12997-13002. PubMed ID: 27799534
[TBL] [Abstract][Full Text] [Related]
4. Rapid peptide-based screening on the substrate specificity of severe acute respiratory syndrome (SARS) coronavirus 3C-like protease by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
Chu LH; Choy WY; Tsai SN; Rao Z; Ngai SM
Protein Sci; 2006 Apr; 15(4):699-709. PubMed ID: 16600962
[TBL] [Abstract][Full Text] [Related]
5. Characterization of Self-Processing Activities and Substrate Specificities of Porcine Torovirus 3C-Like Protease.
Xu S; Zhou J; Chen Y; Tong X; Wang Z; Guo J; Chen J; Fang L; Wang D; Xiao S
J Virol; 2020 Sep; 94(20):. PubMed ID: 32727876
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic insights into COVID-19 by global analysis of the SARS-CoV-2 3CL
Pablos I; Machado Y; de Jesus HCR; Mohamud Y; Kappelhoff R; Lindskog C; Vlok M; Bell PA; Butler GS; Grin PM; Cao QT; Nguyen JP; Solis N; Abbina S; Rut W; Vederas JC; Szekely L; Szakos A; Drag M; Kizhakkedathu JN; Mossman K; Hirota JA; Jan E; Luo H; Banerjee A; Overall CM
Cell Rep; 2021 Oct; 37(4):109892. PubMed ID: 34672947
[TBL] [Abstract][Full Text] [Related]
7. Screening potential FDA-approved inhibitors of the SARS-CoV-2 major protease 3CL
Liu WS; Li HG; Ding CH; Zhang HX; Wang RR; Li JQ
Aging (Albany NY); 2021 Mar; 13(5):6258-6272. PubMed ID: 33678621
[TBL] [Abstract][Full Text] [Related]
8. Profiling of substrate specificity of SARS-CoV 3CL.
Chuck CP; Chong LT; Chen C; Chow HF; Wan DC; Wong KB
PLoS One; 2010 Oct; 5(10):e13197. PubMed ID: 20949131
[TBL] [Abstract][Full Text] [Related]
9. Allosteric Regulation of 3CL Protease of SARS-CoV-2 and SARS-CoV Observed in the Crystal Structure Ensemble.
Kidera A; Moritsugu K; Ekimoto T; Ikeguchi M
J Mol Biol; 2021 Dec; 433(24):167324. PubMed ID: 34717972
[TBL] [Abstract][Full Text] [Related]
10. Profiling of substrate specificities of 3C-like proteases from group 1, 2a, 2b, and 3 coronaviruses.
Chuck CP; Chow HF; Wan DC; Wong KB
PLoS One; 2011; 6(11):e27228. PubMed ID: 22073294
[TBL] [Abstract][Full Text] [Related]
11. Cleavage specificity analysis of six type II transmembrane serine proteases (TTSPs) using PICS with proteome-derived peptide libraries.
Barré O; Dufour A; Eckhard U; Kappelhoff R; Béliveau F; Leduc R; Overall CM
PLoS One; 2014; 9(9):e105984. PubMed ID: 25211023
[TBL] [Abstract][Full Text] [Related]
12. The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease.
Chiou WC; Chen JC; Chen YT; Yang JM; Hwang LH; Lyu YS; Yang HY; Huang C
Biochem Biophys Res Commun; 2022 Feb; 591():130-136. PubMed ID: 33454058
[TBL] [Abstract][Full Text] [Related]
13. Insights into cleavage specificity from the crystal structure of foot-and-mouth disease virus 3C protease complexed with a peptide substrate.
Zunszain PA; Knox SR; Sweeney TR; Yang J; Roqué-Rosell N; Belsham GJ; Leatherbarrow RJ; Curry S
J Mol Biol; 2010 Jan; 395(2):375-89. PubMed ID: 19883658
[TBL] [Abstract][Full Text] [Related]
14. Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease.
Zhu L; George S; Schmidt MF; Al-Gharabli SI; Rademann J; Hilgenfeld R
Antiviral Res; 2011 Nov; 92(2):204-12. PubMed ID: 21854807
[TBL] [Abstract][Full Text] [Related]
15. N-Terminomics for the Identification of In Vitro Substrates and Cleavage Site Specificity of the SARS-CoV-2 Main Protease.
Koudelka T; Boger J; Henkel A; Schönherr R; Krantz S; Fuchs S; Rodríguez E; Redecke L; Tholey A
Proteomics; 2021 Jan; 21(2):e2000246. PubMed ID: 33111431
[TBL] [Abstract][Full Text] [Related]
16. Identification of Host Cellular Protein Substrates of SARS-COV-2 Main Protease.
Miczi M; Golda M; Kunkli B; Nagy T; Tőzsér J; Mótyán JA
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33333742
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the P2' and P3' specificities of thrombin using fluorescence-quenched substrates and mapping of the subsites by mutagenesis.
Le Bonniec BF; Myles T; Johnson T; Knight CG; Tapparelli C; Stone SR
Biochemistry; 1996 Jun; 35(22):7114-22. PubMed ID: 8679538
[TBL] [Abstract][Full Text] [Related]
18. Proteomic identification of protease cleavage sites characterizes prime and non-prime specificity of cysteine cathepsins B, L, and S.
Biniossek ML; Nägler DK; Becker-Pauly C; Schilling O
J Proteome Res; 2011 Dec; 10(12):5363-73. PubMed ID: 21967108
[TBL] [Abstract][Full Text] [Related]
19. Snake venom serine proteinases specificity mapping by proteomic identification of cleavage sites.
Zelanis A; Huesgen PF; Oliveira AK; Tashima AK; Serrano SM; Overall CM
J Proteomics; 2015 Jan; 113():260-7. PubMed ID: 25452133
[TBL] [Abstract][Full Text] [Related]
20. Determination of the P1', P2' and P3' subsite-specificity of factor Xa.
Ludeman JP; Pike RN; Bromfield KM; Duggan PJ; Cianci J; Le Bonniec B; Whisstock JC; Bottomley SP
Int J Biochem Cell Biol; 2003 Feb; 35(2):221-5. PubMed ID: 12479872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
